News & Updates
Filter by Specialty:
Long-term tapinarof use proven safe, effective in plaque psoriasis
Continuous and intermittent use of tapinarof cream 1% once daily (QD) for up to 1 year is effective in patients with mild-to-severe plaque psoriasis, without serious safety concerns, according to a study. In addition, it has shown durable efficacy and a remittive effect of at least 4 months off therapy.
Long-term tapinarof use proven safe, effective in plaque psoriasis
21 Oct 2022
Peanut intake may help with weight loss
In the context of an energy-restricted diet, a weight-loss diet involving daily consumption of 70 g of lightly salted dry-roasted peanuts yielded similar weight loss results as a traditional low-fat weight-loss diet after 6 months in adults at high risk for type 2 diabetes (T2D), a study has shown.
Peanut intake may help with weight loss
21 Oct 2022
Potassium competitive acid blockers go toe-to-toe with PPI in gastric acid diseases
Vonoprazan, a potassium competitive acid blocker (PCAB), is better than proton pump inhibitors (PPI) for the treatment of Helicobacter pylori and erosive oesophagitis, according to a new meta-analysis.
Potassium competitive acid blockers go toe-to-toe with PPI in gastric acid diseases
21 Oct 2022
Risk management program cuts plasma triglycerides in T2D
A 2-week comprehensive risk-management regimen can successfully suppress levels of plasma triglycerides in patients with type 2 diabetes (T2D), a recent study reported.
Risk management program cuts plasma triglycerides in T2D
21 Oct 2022
Amphilimus- vs zotarolimus-eluting stents: Any preference in patients with diabetes?
Updated results of the SUGAR* trial showed that using polymer-free amphilimus-eluting stents (AES) was not a superior option to durable-polymer zotarolimus-eluting stents (ZES) in patients with diabetes mellitus who required percutaneous coronary intervention (PCI).